Carl Zeiss Meditec AG
Clinical trials sponsored by Carl Zeiss Meditec AG, explained in plain language.
A medical technology company providing ophthalmic surgical and diagnostic devices.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New lens aims to sharpen vision after cataract surgery
Disease control CompletedThis study tested a new type of artificial lens, called the AT ELANA 841P, for people having cataract surgery. 284 adults with cataracts in both eyes received either the new lens or a standard lens. Researchers measured how well patients could see at different distances and check…
Sponsor: Carl Zeiss Meditec, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Laser breakthrough: new procedure aims to zap away nearsightedness
Disease control CompletedThis completed Phase 1 trial tested the VisuMax femtosecond laser to correct nearsightedness (myopia) in 357 adults aged 22 and older. The procedure removes a small lens-shaped piece of the cornea to reshape the eye and improve vision. Researchers measured how well the treatment …
Phase 1 • Sponsor: Carl Zeiss Meditec, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC